BAJAJ BROKING
Mankind Pharma plans a ₹3,000-crore QIP at ₹2,520/share, causing a 2.9% equity dilution. Funds will repay debt linked to its ₹14,000-crore Bharat Serums acquisition.
Mankind Pharma is gearing up to launch a Qualified Institutional Placement (QIP) to raise ₹3,000 crore. The issue price is expected to be approximately ₹2,520 per share, resulting in an estimated 2.9% equity dilution post-issue. The funds will primarily be used to repay debt incurred during the ₹14,000-crore acquisition of Bharat Serums and Vaccines (BSV).
Also read: Gravita India Launches ₹750-Crore QIP at ₹2,206.49/Share Floor Price
QIP Details: ₹3,000 crore at ₹2,520/share, 2.9% equity dilution expected.
Purpose: Debt repayment for BSV acquisition.
Mankind Pharma Share Price: Shares recently settled at ₹2,686.05 on NSE, reflecting a strong 35% YTD gain.
Also read: ADIA to Divest ₹1,903-Crore Stake in Mindspace REIT at ₹350/Share
The ₹14,000-crore acquisition of Bharat Serums and Vaccines was financed through a mix of reserves, loans, and the upcoming QIP. Mankind Pharma allocated ₹4,000 crore from its reserves, while ₹7,000 crore was secured via loans. The remaining ₹3,000 crore will be raised through the QIP, bolstering its financial stability for long-term growth.
Mankind Pharma posted impressive financial results for Q2 FY25, showing robust growth across key metrics:
Metric | Q2 FY25 | Q2 FY24 | Growth (%) |
Net Profit | ₹653.5 crore | ₹501 crore | 30.4% |
Revenue from Operations | ₹3,076.5 crore | ₹2,708.1 crore | 13.6% |
EBITDA | ₹850 crore | ₹682.6 crore | 24.5% |
Mankind Pharma’s IPO in April 2023 marked one of the biggest public offerings by a pharma company in recent years, raising ₹4,326 crore. Since its listing at ₹1,300 per share, the Mankind Pharma share price has surged over 90%, delivering a strong return to investors. The stock settled at ₹2,686.05 on Monday, up 1.7%, reflecting continued investor confidence.
Mankind Pharma’s ₹3,000-crore QIP underscores its strategic focus on managing its debt burden while maintaining strong financial performance. With the recent BSV acquisition and steady growth across key metrics, the company remains poised for long-term success.
Also read: HCC Launches ₹400-Crore QIP with Floor Price of ₹45
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading